ERBB2 and invasive breast carcinoma: The HER2-negative subtype of invasive breast cancer includes two genomically distinct categories, labelled as luminal A and luminal B. The latter group has a diminished response to hormonal manipulation therapy and is associated with an inferior prognosis [9].